<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/AB534209-3172-41E0-A85E-143F22107607"><gtr:id>AB534209-3172-41E0-A85E-143F22107607</gtr:id><gtr:name>Harvard School of Public Health</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/16C42590-30C0-4CCE-894F-C4189A4DE800"><gtr:id>16C42590-30C0-4CCE-894F-C4189A4DE800</gtr:id><gtr:name>University of Bordeaux I</gtr:name><gtr:address><gtr:line1>351 Cours de la Liberation</gtr:line1><gtr:postCode>F-33405</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>France</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/AB534209-3172-41E0-A85E-143F22107607"><gtr:id>AB534209-3172-41E0-A85E-143F22107607</gtr:id><gtr:name>Harvard School of Public Health</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/90141738-E924-42D2-A5E2-B221B3866AFA"><gtr:id>90141738-E924-42D2-A5E2-B221B3866AFA</gtr:id><gtr:firstName>Becca</gtr:firstName><gtr:surname>Asquith</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0601072"><gtr:id>D078962F-2717-4E03-ADDD-FC148D75AD45</gtr:id><gtr:title>What Constitutes a Protective CTL Response in HIV-1 Infection?</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0601072</gtr:grantReference><gtr:abstractText>What constitutes a good immune response? Why do some HIV-infected people develop AIDS in months whilst others remain healthy for decades? How do your genes affect your outcome of infection? These are the fundamental questions that we are trying to answer. 

The size of the HIV pandemic is staggering. In some areas of sub-Saharan Africa 1 in every 3 adults are infected. A cheap effective vaccine is desperately needed. The first step in designing an HIV vaccine is understanding the type of immunity that it should induce, i.e. what exactly is a good immune response? 

Answering this question is complicated by the fact that HIV destroys immune cells. Consequently we cannot tell if immune response attributes associated with good viral control are a cause or an effect of low levels of virus. This means that many traditional methods of investigating the immune response are redundant. 

A clue as to what determines the efficacy of the human immune response lies in the observation that some people naturally control HIV infection much better than others and that this is, in part, related to the person?s genetic makeup. The aim of this project is to understand what a good immune response is by understanding why some genes result in better immune control than others. 

The research will be conducted by a novel mathematical analysis of existing HIV-infected patient databases. Our results will contribute to our understanding of what constitutes a good immune response. This could have direct implications for human health and HIV vaccine development. More generally, severity of illness for all 3 of the world?s most devastating diseases: AIDS, malaria and TB is partially determined by host genetics. We hope that the methods and insights our research generates will be applicable in all of these cases.</gtr:abstractText><gtr:technicalSummary>AIM: To determine what constitutes a protective CTL response in HIV-1 infection. 

APPROACH. 
Host HLA class I genotype is significantly associated with the outcome of HIV-1 infection. We will perform a meta-analysis of existing experimental data from 3 patient cohorts to determine the mechanisms underlying this association. 

RATIONALE. 
Recent data has shown that HIV-1 damages the immune system within weeks of infection. Consequently, it is difficult to ascertain if many of the CTL attributes previously associated with good immune control e.g. proliferative capacity are the cause, or simply a passive consequence, of low viral load. With host genetic effects the direction of causality is unequivocal. Consequently, by investigating the mechanisms underlying HLA associations we directly investigate the attributes of a protective CTL response.

BACKGROUND. 
HIV-1 continually evolves to escape the host CTL response. It has been hypothesised that escape contributes to AIDS progression but no clear relationship has been demonstrated. Consequently, it is not known whether HIV-1 escape from CTL is an epiphenomenon that might exacerbate disease progression in a few atypical cases or whether it is a significant driving force that leads to AIDS in the majority.

PRELIMINARY DATA. 
We have demonstrated a relationship between HLA protection and viral escape. We found that CTLs restricted by alleles associated with slow progression to AIDS recognised epitopes where escape variants were weakly selected (P=0.008) and occurred infrequently (P=0.017). Epitopes presented by protective alleles were more likely to elicit a CD8+ T cell response (P=0.001, P=0.0007) and less likely to contain sequence variation (P=0.006). A third of HLA-associated AIDS risk was explained by the net selective advantage of escape variants. These results were found across all alleles and epitopes studied, suggesting a universal CTL-dependent mechanism of protection.

PROJECT. 
These data are promising. They show that the strength of selection for escape is a significant determinant of CTL protection and describe why different HLA alleles are associated with different rates of AIDS progression. However, they do not explain what determines CTL selection and consequently cannot be used to guide vaccine design. Here we test hypotheses regarding the basis of the CTL protective effect we have observed; including the contribution of epitope plasticity, CTL breadth and viral attenuation. 

SIGNIFICANCE. 
A prerequisite for rational vaccine design is an understanding of the attributes of protective immunity. More generally, what constitutes a good CTL response and how HLA genotype impacts on CTLs are fundamental questions in biomedicine.</gtr:technicalSummary><gtr:fund><gtr:end>2011-02-28</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>297870</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leeds</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Mathematics Leeds</gtr:department><gtr:description>I2M: Immunology, Imaging and Modelling</gtr:description><gtr:id>EBBF1BC3-34B8-4CE8-9971-060114EAA59D</gtr:id><gtr:impact>currently preparing a proposal for EU FP7 ITN invoving many members of the I2M network. Multidisciplinary: mathematics, immunology, imaging, computer science</gtr:impact><gtr:partnerContribution>contributed to scientific network</gtr:partnerContribution><gtr:piContribution>organised a number of workshops to facillitate collaboration and ideas sharing</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Cancer Institute (NCI)</gtr:department><gtr:description>KIR</gtr:description><gtr:id>516C6F7B-8DF2-4B81-B572-A5025E367B41</gtr:id><gtr:impact>paper PMID: 22022261
multidiciplinary: genetics, mathematics, bioinformatics</gtr:impact><gtr:partnerContribution>Intellectual input</gtr:partnerContribution><gtr:piContribution>Modelled human immunogenetic data</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Harvard School of Public Health</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>NHP</gtr:description><gtr:id>4D423B76-AB53-4EA5-84E9-6448ED372AF1</gtr:id><gtr:impact>published paper: PMID: 21408213
multidiciplinary: immunology, mathematics, statistics</gtr:impact><gtr:partnerContribution>Provision of data from SIV-infected macaques</gtr:partnerContribution><gtr:piContribution>Model data to quantify the relative importance of different arms of the immune response</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Emory University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>School of Medicine Emory</gtr:department><gtr:description>HAART/depletion</gtr:description><gtr:id>633FF7E5-9CA8-45C6-870E-EEE12078163F</gtr:id><gtr:impact>published paper (PMID:21990968).
Multidisciplinary: experimental immunology and mathematics</gtr:impact><gtr:partnerContribution>Provision of data from NHP models</gtr:partnerContribution><gtr:piContribution>Modelled data to understand why CD8+ T cells do not appear to decrease the lifespan of SIV-infected cells</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bordeaux</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Department of Biostatistics</gtr:department><gtr:description>Bayesian stats</gtr:description><gtr:id>E8C9E443-D0AD-4368-BB92-5539EB0D7675</gtr:id><gtr:impact>published paper: PMID: 21408213
multidiciplinary: immunology, mathematics, statistics</gtr:impact><gtr:partnerContribution>Provision of new techniques for data analysis</gtr:partnerContribution><gtr:piContribution>contribution of novel hypothesis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Robert Busch</gtr:description><gtr:id>6AFF6023-C364-4771-9ADD-E2D76E75F1BE</gtr:id><gtr:impact>grant submitted to Wellcome Trust.
Multidisciplinary: mathematics, immunology, biochemistry</gtr:impact><gtr:partnerContribution>Dr Busch is providing technical guidance on high sensitivity mass spec techniques</gtr:partnerContribution><gtr:piContribution>We will provide mathematical modelling expertise which, combined with Dr Busch's new highly sensitive GC/MS techniques will enable the quantification of turnover of rare cell subsets in vivo</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>work with schoolchildren in London</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A8CD5588-58EF-4E32-B6F1-1C5960FB8308</gtr:id><gtr:impact>prepared work aimed at explaining to year 12/13 students the use of mathematics in biology. As a running example we explain how theoretical immunology contributed to a better understanding and treatment of HIV-infection, providing background information on the HIV epidemic, the role of immunology in the disease and how to describe a (biological) system in equations.

Two school pupils worked with us in the department on a mini-research project, culminating in written and oral presentation of their results</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beautiful Science contd</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9E913B21-14F2-4F27-96D2-903563E32E3D</gtr:id><gtr:impact>Science-art exhibition at Brick Lane Gallery for 1 week.
Schools event attended by about 30 school children.
Public debate.

Very positive feedback. This project has been invited to the Oxford Science Festival, adopted for Faculty Support, adopted by the college as an umbrella for the college's public engagement activities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>invited presentations</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F3055FF8-BEDF-45E2-8178-E7BA0AE97531</gtr:id><gtr:impact>Invited to present at approximately 15 conferences/ universities. Audiences upto about 600.

Generated large amount of interest in my work</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Beautiful Science</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E5E511B6-2B49-4152-9F45-1ED9A12B91AC</gtr:id><gtr:impact>Organising a project in which scientists and artists are working together to exhibit artistic representations of science.

Exhibitions planned for 2012
http://www.beautifulscience.info/</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.beautifulscience.info/</gtr:url><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited chapter in a book</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>F971AF32-00BD-441D-9502-96E3FFF2EEE8</gtr:id><gtr:impact>invited author of chapter in textbook for undergraduates and postgraduates (Mathematical models in biology)

popular book</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008,2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited speaker at International Conferences</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>A6492157-DC5B-49DC-BE63-486F23BECCA5</gtr:id><gtr:impact>Royal Society Frontiers of Science, India 2008 audience: scientists from other disciplines

Disseminated research to non-specialist audience</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>375000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>6CAD7B19-A8B2-4B12-92D9-DACB5FFCFBDC</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>606046</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>47C3AE36-E363-4A82-ADF9-9B8763C7C6D7</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>450000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>project grant</gtr:description><gtr:end>2015-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>2809C0FA-0D68-4D50-A236-B48434B489AB</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>6000</gtr:amountPounds><gtr:country>Japan</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Short term prize fellowship</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Japan Society for the Promotion of Science (JSPS)</gtr:fundingOrg><gtr:id>FAB40BB8-6ADD-4C05-8071-F1A9D8E33E66</gtr:id><gtr:sector>Learned Society</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>324871</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project grant (co-I)</gtr:description><gtr:end>2013-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>45877869-00EA-4E62-A53F-7F02B4DB4FB4</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>113000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>PhD studentship</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:id>E784457B-0BA6-47FD-B157-734BB471E425</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EU FP7 ITN</gtr:description><gtr:end>2018-05-02</gtr:end><gtr:fundingOrg>Community Research and Development Information Service (CORDIS)</gtr:fundingOrg><gtr:id>2B5C6130-3961-4473-86B8-26BC181FFE0A</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1036189</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Investigator Award</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>The Wellcome Trust Ltd</gtr:fundingOrg><gtr:fundingRef>103865</gtr:fundingRef><gtr:id>13B4FA40-D0C5-4C92-908F-A97971881719</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>close to physiological&amp;quot; assay for quantifying CTL lysis in humans</gtr:description><gtr:id>E48875E1-C99B-4FA2-9439-F5BBEAC75CD3</gtr:id><gtr:impact>this assay has been used by a number of groups to quantify CTL lysis in patients</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>assay for quantifying CTL lysis</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Tool to predict T cell epitopes. Available on public repository</gtr:description><gtr:id>D4E46545-246E-4458-A85B-1DB054574F10</gtr:id><gtr:impact>current tests indicate that this is amongst the most accurate prediction software available. Likely to have far reaching consequences for epitope discovery and fundamental research.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Tool to predict T cell epitopes</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>model to analyse in vivo lymphocyte labelling data</gtr:description><gtr:id>26484027-4034-4961-9684-0A84B0810E96</gtr:id><gtr:impact>this model is now widely used by the international scientific community to analyse BrdU and stable-isotope labelling data</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>quantification of lymphocyte turnover</gtr:title><gtr:type>Model of mechanisms or symptoms - human</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>new method to quantify the strength of the CTL response in vivo in HIV/SIV infected humans and non-human primates.</gtr:description><gtr:id>E0D7A3FB-A54D-42E9-BECC-D8BC16E30EE8</gtr:id><gtr:impact>Now widely used by many groups.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>method to quantify CTL efficiency</gtr:title><gtr:type>Data analysis technique</gtr:type><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F275FB30-C632-4EEE-A43C-D01AE9E54C5C"><gtr:id>F275FB30-C632-4EEE-A43C-D01AE9E54C5C</gtr:id><gtr:title>Can non-lytic CD8+ T cells drive HIV-1 escape?</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c5a2690a6f1e86b28f086620dbdb690"><gtr:id>4c5a2690a6f1e86b28f086620dbdb690</gtr:id><gtr:otherNames>Seich Al Basatena NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F3220784-4F57-457A-8800-5FEAEBC39932"><gtr:id>F3220784-4F57-457A-8800-5FEAEBC39932</gtr:id><gtr:title>The immune control of HTLV-1 infection: selection forces and dynamics.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Landmark edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d25d825962b27960f91cde348c7805e0"><gtr:id>d25d825962b27960f91cde348c7805e0</gtr:id><gtr:otherNames>Bangham CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1093-4715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FBCCBA36-0105-4F24-8C9E-BA12579230C2"><gtr:id>FBCCBA36-0105-4F24-8C9E-BA12579230C2</gtr:id><gtr:title>Human neutrophil kinetics: modeling of stable isotope labeling data supports short blood neutrophil half-lives.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/e0d5f79aa7944f2573f6a755739b87e2"><gtr:id>e0d5f79aa7944f2573f6a755739b87e2</gtr:id><gtr:otherNames>Lahoz-Beneytez J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FEE9BE7E-BF02-4EF3-A28F-5CC843F12BDB"><gtr:id>FEE9BE7E-BF02-4EF3-A28F-5CC843F12BDB</gtr:id><gtr:title>In vivo expression of human T-lymphotropic virus type 1 basic leucine-zipper protein generates specific CD8+ and CD4+ T-lymphocyte responses that correlate with clinical outcome.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d64879a57079580f47378b1b23fcfb6a"><gtr:id>d64879a57079580f47378b1b23fcfb6a</gtr:id><gtr:otherNames>Hilburn S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/FE5AF38C-04AB-4F60-B744-490C8E15749B"><gtr:id>FE5AF38C-04AB-4F60-B744-490C8E15749B</gtr:id><gtr:title>Safety of long-term treatment of HAM/TSP patients with valproic acid.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1080b09613a9bad0d846fea801f967af"><gtr:id>1080b09613a9bad0d846fea801f967af</gtr:id><gtr:otherNames>Olindo S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/253504B3-EBCA-472C-8EEE-15806E1388AB"><gtr:id>253504B3-EBCA-472C-8EEE-15806E1388AB</gtr:id><gtr:title>HLA class I binding of HBZ determines outcome in HTLV-1 infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1a69721bba98078147f0347716c38c21"><gtr:id>1a69721bba98078147f0347716c38c21</gtr:id><gtr:otherNames>Macnamara A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5BD75148-E5E4-41F6-9EB6-F2D4B3887176"><gtr:id>5BD75148-E5E4-41F6-9EB6-F2D4B3887176</gtr:id><gtr:title>HTLV-1: persistence and pathogenesis.</gtr:title><gtr:parentPublicationTitle>Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1bf52149cfa6e3f76da9a3d7c85873ec"><gtr:id>1bf52149cfa6e3f76da9a3d7c85873ec</gtr:id><gtr:otherNames>Cook LB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0042-6822</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C501BB4-F3A0-4474-A304-89D407A077B8"><gtr:id>9C501BB4-F3A0-4474-A304-89D407A077B8</gtr:id><gtr:title>The avidity and lytic efficiency of the CTL response to HTLV-1.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/24bee86d35b2180e7d32e6efce47ded1"><gtr:id>24bee86d35b2180e7d32e6efce47ded1</gtr:id><gtr:otherNames>Kattan T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A13363B1-4576-4F3C-901F-1F1ED8F133D4"><gtr:id>A13363B1-4576-4F3C-901F-1F1ED8F133D4</gtr:id><gtr:title>Strongyloidiasis and infective dermatitis alter human T lymphotropic virus-1 clonality in vivo.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/466a9492063ce8d29020ef414f7dd5a6"><gtr:id>466a9492063ce8d29020ef414f7dd5a6</gtr:id><gtr:otherNames>Gillet NA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/98C1AE23-7AA1-4AFA-8220-DF09385894E5"><gtr:id>98C1AE23-7AA1-4AFA-8220-DF09385894E5</gtr:id><gtr:title>Closing the gap between T-cell life span estimates from stable isotope-labeling studies in mice and humans.</gtr:title><gtr:parentPublicationTitle>Blood</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/aa75fc47d835a2ecb0db296abd211e72"><gtr:id>aa75fc47d835a2ecb0db296abd211e72</gtr:id><gtr:otherNames>Westera L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F1346180-DE81-474D-B47C-68EB3A094718"><gtr:id>F1346180-DE81-474D-B47C-68EB3A094718</gtr:id><gtr:title>The immune control of HTLV-1 infection: selection forces and dynamics.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Landmark edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d25d825962b27960f91cde348c7805e0"><gtr:id>d25d825962b27960f91cde348c7805e0</gtr:id><gtr:otherNames>Bangham CR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1093-4715</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/BFC70F48-1005-4496-970B-43BC63F5EA72"><gtr:id>BFC70F48-1005-4496-970B-43BC63F5EA72</gtr:id><gtr:title>Short communication an interferon-? ELISPOT assay with two cytotoxic T cell epitopes derived from HTLV-1 tax region 161-233 discriminates HTLV-1-associated myelopathy/tropical spastic paraparesis patients from asymptomatic HTLV-1 carriers in a Peruvian population.</gtr:title><gtr:parentPublicationTitle>AIDS research and human retroviruses</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/33e0d889dd75e251d51507404a321180"><gtr:id>33e0d889dd75e251d51507404a321180</gtr:id><gtr:otherNames>Best I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0889-2229</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1FC2272B-0C8F-4DBF-9174-153E66081A6C"><gtr:id>1FC2272B-0C8F-4DBF-9174-153E66081A6C</gtr:id><gtr:title>Lymphocyte kinetics in health and disease.</gtr:title><gtr:parentPublicationTitle>Trends in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0647553140d22ce5daa9e5ac13040ca8"><gtr:id>0647553140d22ce5daa9e5ac13040ca8</gtr:id><gtr:otherNames>Asquith B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1471-4906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C3E1E030-B733-41AA-A0D5-D1A58F94EAF4"><gtr:id>C3E1E030-B733-41AA-A0D5-D1A58F94EAF4</gtr:id><gtr:title>KIR2DL2 enhances protective and detrimental HLA class I-mediated immunity in chronic viral infection.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/4c5a2690a6f1e86b28f086620dbdb690"><gtr:id>4c5a2690a6f1e86b28f086620dbdb690</gtr:id><gtr:otherNames>Seich Al Basatena NK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0AF164C1-F589-4EF6-8D10-C3559E516739"><gtr:id>0AF164C1-F589-4EF6-8D10-C3559E516739</gtr:id><gtr:title>Gene activation therapy: from the BLV model to HAM/TSP patients.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Scholar edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3842e55c9edbe767555ef30f85b6e746"><gtr:id>3842e55c9edbe767555ef30f85b6e746</gtr:id><gtr:otherNames>Lezin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1945-0516</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/41B35FE9-3CBB-4F1F-BF90-6423564821E6"><gtr:id>41B35FE9-3CBB-4F1F-BF90-6423564821E6</gtr:id><gtr:title>Why don't CD8+ T cells reduce the lifespan of SIV-infected cells in vivo?</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce12e2f9902881169843b54b0c95de90"><gtr:id>ce12e2f9902881169843b54b0c95de90</gtr:id><gtr:otherNames>Elemans M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F5A5C1F-7A71-4F62-B2C0-9FD0B4DE8075"><gtr:id>0F5A5C1F-7A71-4F62-B2C0-9FD0B4DE8075</gtr:id><gtr:title>Viral expression directs the fate of B cells in bovine leukemia virus-infected sheep.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/40f7599c046ff679491bd609abb71300"><gtr:id>40f7599c046ff679491bd609abb71300</gtr:id><gtr:otherNames>Florins A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/709415F3-1CCD-4FC9-AD8D-1D1F3BE9BB2A"><gtr:id>709415F3-1CCD-4FC9-AD8D-1D1F3BE9BB2A</gtr:id><gtr:title>T-cell epitope prediction: rescaling can mask biological variation between MHC molecules.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0d7d43d2c54f153e2f77e1446a9c191a"><gtr:id>0d7d43d2c54f153e2f77e1446a9c191a</gtr:id><gtr:otherNames>MacNamara A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DB6B97C3-A654-4AFE-868A-31116836A837"><gtr:id>DB6B97C3-A654-4AFE-868A-31116836A837</gtr:id><gtr:title>The evolutionary selective advantage of HIV-1 escape variants and the contribution of escape to the HLA-associated risk of AIDS progression.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0647553140d22ce5daa9e5ac13040ca8"><gtr:id>0647553140d22ce5daa9e5ac13040ca8</gtr:id><gtr:otherNames>Asquith B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D7A34EC4-889E-46D9-A2FE-7920789DCE1C"><gtr:id>D7A34EC4-889E-46D9-A2FE-7920789DCE1C</gtr:id><gtr:title>Quantifying the impact of human immunodeficiency virus-1 escape from cytotoxic T-lymphocytes.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/144744fc2e21fa81acd4a1517b1e229e"><gtr:id>144744fc2e21fa81acd4a1517b1e229e</gtr:id><gtr:otherNames>Kadolsky UD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/9C47F9A0-7DAF-45C4-AD1E-C2FEA6ABEC17"><gtr:id>9C47F9A0-7DAF-45C4-AD1E-C2FEA6ABEC17</gtr:id><gtr:title>The efficiency of the human CD8+ T cell response: how should we quantify it, what determines it, and does it matter?</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce12e2f9902881169843b54b0c95de90"><gtr:id>ce12e2f9902881169843b54b0c95de90</gtr:id><gtr:otherNames>Elemans M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/154BB770-D5EF-40C3-B635-8EB716FE2ED8"><gtr:id>154BB770-D5EF-40C3-B635-8EB716FE2ED8</gtr:id><gtr:title>Quantification of the relative importance of CTL, B cell, NK cell, and target cell limitation in the control of primary SIV-infection.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce12e2f9902881169843b54b0c95de90"><gtr:id>ce12e2f9902881169843b54b0c95de90</gtr:id><gtr:otherNames>Elemans M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/EF2A7A00-A70D-4F67-9F41-EA2E9D009E21"><gtr:id>EF2A7A00-A70D-4F67-9F41-EA2E9D009E21</gtr:id><gtr:title>Gene activation therapy: from the BLV model to HAM/TSP patients.</gtr:title><gtr:parentPublicationTitle>Frontiers in bioscience (Scholar edition)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3842e55c9edbe767555ef30f85b6e746"><gtr:id>3842e55c9edbe767555ef30f85b6e746</gtr:id><gtr:otherNames>Lezin A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1945-0516</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B81AD747-364A-441D-A7F5-CCAD45C9BDD5"><gtr:id>B81AD747-364A-441D-A7F5-CCAD45C9BDD5</gtr:id><gtr:title>In contrast to HIV, KIR3DS1 does not influence outcome in HTLV-1 retroviral infection.</gtr:title><gtr:parentPublicationTitle>Human immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/3eae3a884f3ae8bfaadfbf979e44604c"><gtr:id>3eae3a884f3ae8bfaadfbf979e44604c</gtr:id><gtr:otherNames>O'Connor GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0198-8859</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/77C197A5-188D-481C-B0B5-192CF9849F84"><gtr:id>77C197A5-188D-481C-B0B5-192CF9849F84</gtr:id><gtr:title>Rates of CTL killing in persistent viral infection in vivo.</gtr:title><gtr:parentPublicationTitle>PLoS computational biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce12e2f9902881169843b54b0c95de90"><gtr:id>ce12e2f9902881169843b54b0c95de90</gtr:id><gtr:otherNames>Elemans M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-734X</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601072</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>